Breast cancer patients with BRCA1 mutation experience pCR after neoadjuvent chemother
 

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

More...